ArticlemedRxiv : the preprint server for health sciences2025
Concentrations and Estimated Daily Intake of Legacy and Emerging PFAS in the Milk of Women Residing in the Greater Cincinnati Area.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: Per- and polyfluoroalkyl substances (PFAS) have been reported in human milk. However, prior U.S. studies have not included novel PFAS alternatives of emerging concern or infants' Estimated Daily Intake (EDI) of PFAS. Methods: Human milk was collected between 2019 and 2020 at 6 weeks after delivery from 100 Cincinnati, Ohio, nursing women participants in the IMPRINT study; 29 PFAS congeners were measured using ultrahigh performance liquid chromatography-mass spectrometry. We performed descriptive exposure analyses and assessed infant's PFAS EDI from human milk. Results: All human milk samples contained PFAS. Of the 19 PFAS detected, 5 congeners were concurrently found in ≥ 50% of the samples. Legacy PFAS had the highest detection frequencies and concentrations: 97.7% for perfluorooctanesulfonic acid (PFOS) (median concentration: 14.5 ng/L) and 89.8% for perfluorooctanoic acid (PFOA) (median: 17.4 ng/L), 71.6% for perfluorohexanesulfonic acid (PFHxS) (median: 3.7 ng/L), and 70.0% for perfluorohexanoic acid (PFHxA) (median: 10.4 ng/L). An emerging PFAS, dodecafluoro-3H-4,8-dioxanonanoate (ADONA), was detected in 68.0% of samples (median: 3.5 ng/L). The PFAS with the highest EDI included PFOA (median: 8.6 ng), PFOS (median: 7.1 ng), and PFHxA (median: 5.8 ng). About 98% of samples had PFAS levels above the European Food Safety Authority (EFSA) tolerable weekly intake of 4.4 ng/kg body weight/week for the sum of PFOA, PFOS, PFHxS and perfluorononanoate (PFNA). Conclusions: Human milk from women in Cincinnati, Ohio, contained both legacy and emerging PFAS and infants' PFAS consumption through breastfeeding exceeded EFSA tolerable weekly intakes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.